Skip to main content
Log in

Hodgkin-Lymphom im fortgeschrittenen Stadium

BEACOPPeskaliert oder ABVD: Lässt sich durch PET-Steuerung die Therapie deeskaliert fortsetzen?

  • journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

1

Literatur

  1. Skoetz N et al. Lancet Oncol. 2013;14(10):943–52

    Article  Google Scholar 

  2. Borchmann P et al. Lancet. 2018;390(10114):2790–802

    Article  Google Scholar 

  3. Casasnovas RO et al. Lancet Oncol. 2019;20(2):202–15

    Article  Google Scholar 

  4. Johnson P et al. N Engl J Med. 2016;374(25):2419–29

    Article  Google Scholar 

  5. Connors JM et al. N Engl J Med. 2018;378(4):331–44

    Article  CAS  Google Scholar 

  6. Bröckelmann PJ et al. Dtsch Arztebl Int. 2018;115(31-32):535–40

    PubMed  Google Scholar 

Literatur

  • Casasnovas RO et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–15

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul J. Bröckelmann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bröckelmann, P.J. BEACOPPeskaliert oder ABVD: Lässt sich durch PET-Steuerung die Therapie deeskaliert fortsetzen?. Info Onkol. 22, 26–27 (2019). https://doi.org/10.1007/s15004-019-6702-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6702-y

Navigation